List of Excipients in Branded Drug OPCON-A

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	OPCON-A	naphazoline hydrochloride and pheniramine maleate	24208-430	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	OPCON-A	naphazoline hydrochloride and pheniramine maleate	24208-430	BORIC ACID
Bausch & Lomb Incorporated	OPCON-A	naphazoline hydrochloride and pheniramine maleate	24208-430	EDETATE DISODIUM
Bausch & Lomb Incorporated	OPCON-A	naphazoline hydrochloride and pheniramine maleate	24208-430	HYDROCHLORIC ACID
Bausch & Lomb Incorporated	OPCON-A	naphazoline hydrochloride and pheniramine maleate	24208-430	HYPROMELLOSE

# OPCON-A Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

OPCON-A is an over-the-counter ophthalmic solution combining naphazoline hydrochloride 0.025% and pheniramine maleate 0.3% for temporary relief of redness and itching caused by allergies. Its excipient system is conventional, low-cost, and compatible with multidose ophthalmic packaging. Commercial opportunity is therefore more likely to come from preservative-free delivery, improved tolerability, longer shelf life, private-label supply, and differentiated packaging than from composition-of-matter exclusivity.

The marketed formulation uses a borate buffer, chelating agent, purified water, and benzalkonium chloride preservative. The product is regulated under the FDA nonprescription ophthalmic monograph framework rather than through a conventional prescription-drug exclusivity model. [1][2]

What is the OPCON-A formulation?

OPCON-A contains two active ingredients:

Component	Concentration	Function
Naphazoline hydrochloride	0.025%	Ophthalmic vasoconstrictor; reduces ocular redness
Pheniramine maleate	0.3%	Histamine H1 antagonist; reduces allergic itching

The labeled inactive ingredients are benzalkonium chloride, boric acid, edetate disodium, purified water, sodium borate, and pH-adjusting agents, including sodium hydroxide and hydrochloric acid. [1]

What does each excipient do?

Excipient	Primary formulation role	Commercial relevance
Benzalkonium chloride	Multidose preservative	Low cost and established, but creates tolerability and chronic-use concerns
Boric acid and sodium borate	Buffer system and tonicity contribution	Familiar ophthalmic excipients with broad supply availability
Edetate disodium	Chelating agent	Improves preservative performance by binding metal ions
Purified water	Vehicle	Standard ophthalmic solvent
Sodium hydroxide and hydrochloric acid	pH adjustment	Supports ocular comfort and active-ingredient stability

The excipient system is designed for a conventional aqueous multidose eye drop. It does not rely on a specialized delivery platform, viscosity-enhancing polymer, suspension technology, liposomal carrier, or in situ gel.

What excipient strategy does OPCON-A use?

OPCON-A uses a standard preservative-buffered aqueous strategy with four commercial advantages.

First, the formulation is manufacturable using common ophthalmic equipment. The process generally requires compounding, pH adjustment, sterile filtration or validated sterilization controls, aseptic filling, and packaging in a multidose dropper.

Second, the system supports a relatively low-cost retail product. Borate buffers, edetate disodium, purified water, and benzalkonium chloride are commodity or widely available pharmaceutical excipients.

Third, the formulation supports multidose use without requiring a preservative-free container-closure system. That lowers packaging cost and simplifies consumer handling.

Fourth, the system is familiar to regulators and contract manufacturers. The formulation does not require clinical validation of a novel delivery mechanism to establish basic product performance.

The main limitation is benzalkonium chloride. Repeated exposure to benzalkonium chloride can be associated with ocular-surface irritation, tear-film disruption, and reduced suitability for frequent or prolonged use. That limitation creates the clearest product-development opportunity.

What commercial opportunities exist for OPCON-A excipient innovation?

Can a preservative-free OPCON-A alternative compete?

Yes. A preservative-free version could target consumers with sensitive eyes, contact-lens users where labeling permits, and patients who use allergy drops repeatedly during seasonal exposure.

Potential systems include:

• Unit-dose sterile ampoules
• Multidose preservative-free pumps
• One-way valve droppers
• Airless ophthalmic containers
• Preservative-free bottles using microbial-barrier technology

The active ingredients would remain familiar, while the excipient and container-closure system would create differentiation. The commercial tradeoff is higher packaging cost, more complex filling, and greater device-validation requirements.

A preservative-free product would need to demonstrate container integrity, microbial control throughout labeled use, dose uniformity, extractables and leachables control, and stability after opening or repeated actuation.

Could a low-irritation buffered formulation improve the product?

A revised buffer system could reduce formulation-related discomfort while maintaining the required pH and osmolality range. Candidate approaches include:

• Lower total buffer concentration
• Alternative borate-phosphate systems
• Tonicity adjustment with sodium chloride or other ophthalmically accepted agents
• Reduced preservative concentration where microbiological validation supports it
• Preservative-free packaging

The primary technical constraint is compatibility between active ingredients, pH, preservative effectiveness, container materials, and ocular comfort. Any buffer change would require comparative stability and performance testing.

Is there an opportunity for a viscosity-enhanced product?

A lightly viscosity-enhanced formulation could increase ocular residence time and reduce drainage. Candidate excipients include hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, polyethylene glycol, carbomers, or hyaluronic-acid-based polymers.

A viscosity strategy could support claims or positioning such as:

• Longer-lasting comfort
• Reduced dosing frequency
• Improved drop retention
• Added lubrication for allergy-associated dryness

The risk is that viscosity can affect drop size, administration ease, blur, preservative distribution, and consumer acceptance. Excessive viscosity may make the product feel sticky or delay visual recovery after instillation.

Can excipients support a dual allergy-and-dry-eye positioning?

OPCON-A primarily addresses itching and redness. Many ocular-allergy consumers also experience burning, watering, and ocular-surface discomfort. A formulation with a compatible lubricant could target that broader symptom profile.

Potential excipient platforms include:

Platform	Potential benefit	Main constraint
Povidone	Lubrication and wetting	Limited differentiation at low concentrations
Hydroxypropyl methylcellulose	Increased retention and comfort	May increase viscosity and blur
Polyethylene glycol	Lubrication	Requires compatibility and preservative testing
Hyaluronic acid	Surface hydration and retention	Higher cost and greater formulation complexity
Lipid-based system	Evaporation and tear-film support	May affect clarity and dropper performance

The regulatory pathway depends on the intended claim. A product that retains the existing OTC allergy indications but adds supportive comfort benefits may be easier to position than a product making independent dry-eye treatment claims.

What regulatory pathway applies to OPCON-A?

OPCON-A is an OTC ophthalmic drug product. Naphazoline hydrochloride and pheniramine maleate are recognized active ingredients for temporary relief of redness and itching when used within the applicable FDA monograph conditions. [2]

The relevant framework is the FDA OTC monograph for ophthalmic drug products, including requirements concerning active ingredients, concentrations, labeling, warnings, directions, and dosage forms. The FDA’s final monograph framework is codified under 21 C.F.R. Part 349. [3]

A reformulated product may remain within the OTC monograph if:

• The active ingredients and concentrations remain permitted;
• The dosage form remains covered;
• The labeling complies with the applicable Drug Facts requirements;
• The excipients are suitable for ophthalmic use;
• The product satisfies current manufacturing and quality requirements.

A material change in active ingredients, indication, dosage form, or labeling could require an FDA submission outside the monograph pathway.

What is the Orange Book status of OPCON-A?

OPCON-A is not positioned like a conventional prescription NDA product with an active Orange Book patent and exclusivity strategy. OTC monograph products generally do not depend on Orange Book-listed patents to prevent direct competition.

The primary barriers are instead:

• Compliance with the OTC monograph
• Manufacturing quality systems
• Sterile ophthalmic production capacity
• Product registration and listing obligations
• Brand recognition
• Retail distribution
• Packaging and device reliability
• Consumer acceptance

A competitor can typically commercialize a monograph-compliant product without challenging an OPCON-A patent through a Paragraph IV filing. Paragraph IV litigation is therefore not the central entry mechanism for this product category.

What patents protect OPCON-A and its excipient system?

The active ingredients are old, widely used ophthalmic compounds. The conventional OPCON-A excipient combination is unlikely to provide meaningful composition-of-matter protection by itself.

Potential patentable subject matter would more likely involve:

• Preservative-free multidose packaging
• Specific container-closure systems
• Low-irritation preservative systems
• Defined viscosity and osmolality ranges
• Stability improvements
• Manufacturing processes
• Device-controlled drop delivery
• Combination formulations with lubricating polymers
• New packaging configurations

A patent covering only routine excipients at conventional concentrations may face validity and obviousness challenges. Stronger protection would require a demonstrated technical effect, such as improved stability, reduced irritation, enhanced microbial protection, or materially improved dosing performance.

The relevant commercial distinction is between the branded OPCON-A product and the broader formulation concept. A competitor may be able to sell a monograph-compliant naphazoline-pheniramine product while using a different preservative, buffer, polymer, or container.

How strong is the OPCON-A patent estate?

The commercial patent estate appears limited compared with newer prescription ophthalmic products that use novel active ingredients, drug-device combinations, or proprietary delivery technologies.

Protection category	Likely strength for conventional OPCON-A formulation
Active ingredient composition	Low; established ingredients
Conventional buffer system	Low
Benzalkonium chloride preservation	Low
Product-specific manufacturing process	Low to moderate
Preservative-free container system	Moderate to strong if technically differentiated
Viscosity-enhanced formulation	Moderate if supported by unexpected performance
Device-based delivery	Moderate to strong depending on claims
Brand and trade dress	Commercially relevant but separate from patent protection

Trademark, trade dress, retailer relationships, and manufacturing know-how may have greater practical value than patent protection for a conventional OTC product.

When does OPCON-A lose exclusivity?

OPCON-A does not have a single prescription-style patent expiration date that determines generic entry. Competitive entry is governed primarily by the OTC monograph and commercial readiness.

The product’s effective exclusivity is therefore based on:

1. Brand recognition and consumer loyalty.
2. Retail shelf placement.
3. Advertising and seasonal demand.
4. Supply reliability.
5. Packaging convenience.
6. Perceived tolerability.
7. Manufacturer scale.

A private-label or store-brand product can compete without waiting for patent expiry if it complies with the applicable OTC requirements.

Which companies can challenge OPCON-A commercially?

Competition can come from branded and private-label manufacturers selling naphazoline-based redness relievers, pheniramine-containing allergy drops, or alternative antihistamine ophthalmic products.

Competitive categories include:

Competitor type	Product strategy
Store brands	Lower price with monograph-compliant actives
Branded OTC manufacturers	Advertising, packaging, and distribution
Allergy-eye specialists	Antihistamine or mast-cell-stabilizer products
Preservative-free manufacturers	Sensitive-eye and frequent-use positioning
Generic ophthalmic manufacturers	Lower-cost products where applicable
Contract manufacturers	Retailer-specific private-label supply

Products containing ketotifen or other modern OTC allergy actives may compete for the same consumer need while offering different duration, dosing, or tolerability profiles. This creates substitution risk even where the formulation is not chemically identical.

What manufacturing and intellectual-property barriers exist?

The largest operational barrier is sterile ophthalmic manufacturing. A commercial supplier must control:

• Bioburden and sterility
• Particulate contamination
• Fill-volume accuracy
• Drop-size consistency
• Container-closure integrity
• Preservative effectiveness
• Active-ingredient assay
• Degradation products
• Extractables and leachables
• Stability under shipping and consumer-use conditions

For preservative-containing products, the preservative effectiveness test is central. For preservative-free products, the container and delivery system must provide the microbial-control function normally supplied by the preservative.

Manufacturing scale can produce a stronger barrier than formulation IP. A supplier with validated ophthalmic lines, reliable component sourcing, and established retail distribution may outperform a patent holder without equivalent production capacity.

How should a company prioritize OPCON-A formulation opportunities?

A practical development sequence is:

Near-term opportunity: private-label conventional product

A monograph-compliant naphazoline-pheniramine solution offers the lowest development risk. The value proposition is price, retailer access, bottle design, and supply reliability.

Mid-term opportunity: preservative-reduced or preservative-free product

This option offers stronger differentiation and access to sensitive-eye consumers. It requires higher packaging and microbiology investment.

Higher-value opportunity: lubricating allergy formulation

A polymer-containing product could address itching and redness while improving comfort. The main development issues are viscosity, drop size, visual blur, stability, and claim substantiation.

Longer-term opportunity: proprietary delivery system

A multidose preservative-free pump or metered-dose ophthalmic device could support stronger IP and premium pricing. The technical program would need device development, human-factors work, container-closure testing, and regulatory validation.

What revenue exposure does OPCON-A create?

OPCON-A revenue is exposed to substitution rather than classic patent-cliff erosion. Key risks include:

• Retailer migration to private-label products
• Price compression from monograph-compliant competitors
• Consumer movement toward preservative-free products
• Seasonal demand volatility
• Stock-outs caused by sterile manufacturing constraints
• Preference for newer allergy products
• Negative perception of benzalkonium chloride
• Limited differentiation in a conventional aqueous formulation

The strongest revenue-defense strategy is a portfolio rather than a single product. A brand owner could maintain the conventional low-cost product while adding preservative-free, lubricating, travel-size, and premium packaging variants.

Key Takeaways

• OPCON-A contains naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
• Its excipient system is a conventional borate-buffered aqueous formulation with benzalkonium chloride and edetate disodium.
• The main formulation weakness is reliance on a conventional preservative in a product used by consumers with potentially sensitive ocular surfaces.
• Preservative-free packaging is the clearest commercial opportunity.
• Viscosity-enhanced and lubricating formulations could expand the product into allergy-plus-comfort positioning.
• OPCON-A is primarily an OTC monograph product, not a prescription Orange Book exclusivity asset.
• Paragraph IV challenges are not the main competitive mechanism.
• Brand, retail distribution, sterile manufacturing, and packaging know-how may matter more than patent protection.
• Stronger patent opportunities would center on delivery systems, preservative-free containers, stability, and demonstrated tolerability improvements.

FAQs About OPCON-A Excipient and Commercial Strategy

What preservative is used in OPCON-A?

OPCON-A uses benzalkonium chloride as the multidose ophthalmic preservative, according to its product labeling. [1]

Does OPCON-A contain a lubricant?

The conventional formulation is not primarily positioned as a lubricating eye drop. A reformulated product could add a compatible polymer, but that would require stability, preservative, drop-size, and labeling evaluation.

Can a company sell a generic version of OPCON-A?

A company can pursue a monograph-compliant OTC naphazoline-pheniramine product without relying on a Paragraph IV patent challenge. The product must meet FDA requirements for active ingredients, labeling, quality, and manufacturing.

Is a preservative-free OPCON-A formulation patentable?

Potentially. Patent strength would depend on whether the formulation or container system provides a specific, non-obvious technical benefit, such as microbial protection, improved stability, reduced irritation, or consistent multidose delivery.

What is the best premium positioning for an OPCON-A alternative?

The strongest premium position is likely a preservative-free, multidose product with reliable drop dosing and an optional lubricating benefit, supported by evidence of ocular comfort and product stability.

References

1. Bausch + Lomb. (n.d.). OPCON-A eye allergy relief redness reliever antihistamine: Drug facts label. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). OTC monograph M012: Ophthalmic drug products for over-the-counter human use. https://www.accessdata.fda.gov/

3. Code of Federal Regulations. (2024). 21 C.F.R. Part 349: Ophthalmic drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/ current